Advertisement
Advertisement
CELU
Celularity Inc. Class A Common Stock
0.88
USDSponsored
-0.03
-3.04%
May 08, 15:55 UTC -4
Closed
After-Market
0.89
+0.01
+1.03%
CELU Earnings Reports
Positive Surprise Ratio
CELU beat 8 of 15 last estimates.
53%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Celularity Inc. Class A Common Stock earnings per share and revenue
On Apr 30, 2026, CELU reported earnings of -0.85 USD per share (EPS) for Q4 25, beating the estimate of -1.53 USD, resulting in a 44.44% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +2.43% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
FAQ
What were Celularity Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Celularity Inc. Class A Common Stock reported EPS of -$0.85, beating estimates by 44.44%, and revenue of --, -- -- expectations.
How did the market react to Celularity Inc. Class A Common Stock's Q4 2025 earnings?
The stock price moved up 2.43%, changed from $0.93 before the earnings release to $0.96 the day after.
When is Celularity Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Celularity Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Celularity Inc. Class A Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement